Original Research

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration

P William Conrad, David N Zacks, Mark W Johnson

Clinical Ophthalmology 2008, 2:727-733

Published Date: 5 December 2008